TLDR Fastly (FSLY) hit a 52-week high of $25.80 on March 18, up from a 52-week low of $4.65 The stock is up roughly 259% over the past year and 137% year-to-dateTLDR Fastly (FSLY) hit a 52-week high of $25.80 on March 18, up from a 52-week low of $4.65 The stock is up roughly 259% over the past year and 137% year-to-date

Fastly (FSLY) Stock Hits 52-Week High on Debt Relief and Q4 Earnings Beat

2026/03/19 01:45
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Fastly (FSLY) hit a 52-week high of $25.80 on March 18, up from a 52-week low of $4.65
  • The stock is up roughly 259% over the past year and 137% year-to-date
  • Q4 revenue came in at $172.6 million, beating estimates of $161.4 million — a 22% year-over-year jump
  • The stock is surging in part due to relief after its 0% convertible senior notes matured on March 15, removing a debt overhang
  • Fastly posted its first-ever profitable fiscal year, with Q4 EPS of $0.12 vs. the $0.06 analyst estimate

Fastly (FSLY) hit a new 52-week high of $25.80 on Tuesday, as the stock continued a run that has taken it from a low of $4.65 over the past year.


FSLY Stock Card
Fastly, Inc., FSLY

The stock was last trading at $25.81, up 11.08% on the day. That puts its year-to-date gain at roughly 137% and its one-year return at approximately 259%.

The move higher comes as investors digest a strong fourth quarter. Fastly reported Q4 revenue of $172.6 million, beating the consensus estimate of $161.4 million. That’s a 22% increase compared to the same quarter a year ago.

Earnings per share came in at $0.12 for the quarter, beating the analyst estimate of $0.06. Operating profit hit $21.2 million, well above expectations of $10.2 million.

Perhaps more important to Tuesday’s rally, Fastly’s 0% convertible senior notes matured on March 15. The debt had been a source of anxiety for investors in recent weeks, and its resolution appears to have cleared the air.

The stock had sold off in the lead-up to that maturity date. Tuesday’s move looks like a rebound from that pullback, with traders moving back in now that the uncertainty is gone.

Analyst Price Target Upgrades

Wall Street has been playing catch-up with the stock. DA Davidson raised its price target to $13 from $9 after the Q4 results, though it kept a Neutral rating.

RBC Capital went further, lifting its target to $20 from $12. RBC pointed to improved execution and the potential for multiple expansion as reasons for the upgrade.

That $20 target is now well below where the stock is actually trading, suggesting analyst estimates haven’t kept pace with the market’s enthusiasm.

Fastly’s market cap currently sits at $3.67 billion. Average daily trading volume is around 10 million shares, and the technical sentiment signal is rated as a buy.

First Profitable Year

The Q4 results capped what Fastly described as its first-ever profitable fiscal year. That milestone appears to be a key driver behind the renewed investor interest.

InvestingPro data shows a 170% price gain over just the last six months. The same data flags the stock as potentially overvalued relative to its Fair Value estimate, placing it on the “Most Overvalued” list.

Fastly also made a housekeeping change earlier this year, switching its auditing firm from Deloitte & Touche to KPMG for the fiscal year ending December 31, 2026.

The stock’s technical sentiment is currently rated as a buy, per market data as of March 18.

The post Fastly (FSLY) Stock Hits 52-Week High on Debt Relief and Q4 Earnings Beat appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

The post Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference appeared on BitcoinEthereumNews.com. The suitcoiners are in town.  From a low-key, circular podium in the middle of a lavish New York City event hall, Strategy executive chairman Michael Saylor took the mic and opened the Bitcoin Treasuries Unconference event. He joked awkwardly about the orange ties, dresses, caps and other merch to the (mostly male) audience of who’s-who in the bitcoin treasury company world.  Once he got onto the regular beat, it was much of the same: calm and relaxed, speaking freely and with confidence, his keynote was heavy on the metaphors and larger historical stories. Treasury companies are like Rockefeller’s Standard Oil in its early years, Michael Saylor said: We’ve just discovered crude oil and now we’re making sense of the myriad ways in which we can use it — the automobile revolution and jet fuel is still well ahead of us.  Established, trillion-dollar companies not using AI because of “security concerns” make them slow and stupid — just like companies and individuals rejecting digital assets now make them poor and weak.  “I’d like to think that we understood our business five years ago; we didn’t.”  We went from a defensive investment into bitcoin, Saylor said, to opportunistic, to strategic, and finally transformational; “only then did we realize that we were different.” Michael Saylor: You Come Into My Financial History House?! Jokes aside, Michael Saylor is very welcome to the warm waters of our financial past. He acquitted himself honorably by invoking the British Consol — though mispronouncing it, and misdating it to the 1780s; Pelham’s consolidation of debts happened in the 1750s and perpetual government debt existed well before then — and comparing it to the gold standard and the future of bitcoin. He’s right that Strategy’s STRC product in many ways imitates the consols; irredeemable, perpetual debt, issued at par, with…
Share
BitcoinEthereumNews2025/09/18 02:12
Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

The post Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent? appeared on BitcoinEthereumNews.com. In brief The White House registered aliens.gov
Share
BitcoinEthereumNews2026/03/19 05:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26